Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

(2013) R. Panaccione et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

(2011) Mamoru Watanabe et al.   Journal of Crohns & Colitis

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

(2010) R. PANACCIONE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

(2010) William J. Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Development of the Crohnʼs disease digestive damage score, the Lémann score

(2010) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

Inflammatory Bowel Disease

(2009) Clara Abraham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Treatment Response to Infliximab Maintenance Therapy in Crohn's Disease: A Payor Perspective

(2008) Eric Qiong Wu et al.   VALUE IN HEALTH

New global map of Crohnʼs disease: Genetic, environmental, and socioeconomic correlations

(2007) Michael Economou et al.   INFLAMMATORY BOWEL DISEASES